top of page

GENOS IMMUNE PLUS SYSTEMIC REBALANCING

Systemic immune modulation at the receptor level

The functional approach of GENOS Immune Plus

The immune system is not controlled by individual factors, but by a highly complex network of signaling pathways, receptors, and cellular interactions. Dysregulation within this system leads to both chronic inflammation and an inadequate immune response. GENOS Immune Plus addresses this complexity not through an isolated target structure, but through the functional rebalancing of key immunological receptor axes. 

This is made possible by the autocatalytic regulation of key epigenetic processes initiated by RM31®, which optimally targets and regulates methylation, demethylation, acetylation, and phosphorylation at specific sites.

Quality of immune activation

The observed effects can consistently be classified into the following regulatory systems:

Cytokine and growth factor receptors

  • IL-2 receptor (IL-2R): Regulation of T-cell and NK-cell activity

  • IL-6 receptor (IL-6R): Regulation of inflammation and acute-phase response

  • TNF receptor (TNFR): central role in inflammatory and apoptotic processes

  • Interferon receptors (IFNAR, IFNGR): antiviral and antitumor signaling pathways

  • EGF receptor (EGFR): Cell proliferation and growth regulation

Innate immunity and pattern recognition

  • Toll-like receptors (TLR2, TLR4, TLR7, TLR9): recognition of danger signals and initiation of the immune response

They form the starting point of the immune response

Immune regulation and checkpoint systems

  • CD28: costimulatory activation of T cells

  • CTLA-4: negative regulation of the immune response

  • PD-1: central role in immune exhaustion

  • TGF-β receptor: Immunosuppression and tissue regulation

These systems regulate the balance between activation and suppression

Apoptosis and stress regulation

  • Fas receptor (CD95): Initiation of programmed cell apoptosis

This axis regulates cellular stress and elimination mechanisms

Cell migration and tissue distribution

  • Chemokine receptors (CXCR3, CXCR4, CCR5, CCR7): Control of immune cell movement and localization

Immune regulation and checkpoint systems

NK cell-specific regulation

  • NKG2D: activating receptor for the recognition of stressed cells

  • KIR receptors: inhibitory control of NK cell activity

This axis determines the cytotoxic effectiveness of the immune response

Neuroimmunological interfaces

  • β2-adrenergic receptor (β2-AR): Link between the stress system and the immune response

  • Adenosine receptors (A2A, A2B): Regulation of inflammatory and immunosuppressive processes

Central control of immune cells

Sphingosine-1-phosphate (S1P) receptors (S1PR1, S1PR2, and S1PR3) play a central role in regulating immune cell distribution and the systemic immune response. S1P receptors are significantly involved in:

  • Lymphocyte exit from lymphoid organs

  • The return of immune cells to the bloodstream

  • Tissue localization and homing of immune cells

  • Regulation of inflammatory processes

  • Maintenance of immunological homeostasis

They thus determine not only the activity but, above all, the spatial organization of the immune system. While chemokine receptors control the directed movement of immune cells, S1P receptors regulate the global distribution, retention, and circulation of immune cells throughout the entire organism

The S1P axis represents a feedback-sensitive system that enables adaptive regulation:

  • context-dependent activation or suppression of the immune response

  • Adaptation to different pathophysiological situations

  • Restoration of systemic balance

Integrative mechanism of action

The simultaneous modulation of these systems enables:

  • activation of functionally impaired immune cells

  • Stabilization of excessive inflammatory reactions

  • Improvement of cell-cell communication

  • Restoration of immunological balance

GENOS Immune Plus does not act through molecular receptor blockade,

but through the modulation of immune signaling dynamics—functionally reorganizing dysregulated immune networks.

Implications for clinical practice

This approach opens up new perspectives for:

  • complex immunological dysregulations

  • chronic inflammatory conditions

  • functional immune deficiencies

  • systemic diseases with multiple signaling disturbances

Unlike conventional pharmacological approaches that act on isolated molecular targets, GENOS Immune Plus operates on a systems biology level—rebalancing complex immune signaling networks rather than individual pathways.

tab-1.png
Illustration of the GENOS mechanism across all relevant receptors
bottom of page